Post Parker Institute for Cancer Immunotherapy Announces Appointment of Mark Veich as Chief Organizational Advancement Officer
Post Parker Institute for Cancer Immunotherapy Demonstrates Leadership and Showcases Latest Advances in Immunotherapy at SITC 2025 Annual Meeting
Post The Parker Institute for Cancer Immunotherapy Awards Over $1 Million to Five Early Stage Career Researchers Pushing the Boundaries of Cancer Science
Post Immunai and the Parker Institute Collaborate to Build One of the Largest Single-Cell Datasets in Cancer
Post Karen Knudsen, MBA PhD, Appointed Chief Executive Officer of the Parker Institute for Cancer Immunotherapy
Post Owen Witte, Co-Director of PICI at UCLA, Awarded International Harrington Prize for Innovation in Medicine
Post From the Front Lines to the Frontiers of Defeating Breast Cancer with Elizabeth Mittendorf, MD, PhD
Post Cell Therapy Shows Promise Against Deadly Childhood Brain Cancer in Trial Led by Crystal Mackall and Michelle Monje
Post The Parker Institute for Cancer Immunotherapy Awards More Than $1 Million to Four Early Career Investigators
Post Study by Carl June, PICI Center Director at Penn Medicine, Finds No Link Between CAR-T and Secondary Cancers
Post BostonGene and the Parker Institute for Cancer Immunotherapy Collaborate to Generate Comprehensive Longitudinal Multi-Omic Data for Predicting Immunotherapy Outcomes
Post Breakthrough Prize for CAR-T Research Awarded to Carl June, Center Director of PICI at Penn Medicine
Post Parker Institute for Cancer Immunotherapy (PICI) Welcomes Weill Cornell Medicine to Cancer Research Consortium
Post PICI Network Researchers to Present at 2023 Annual Meeting of Society for Immunotherapy of Cancer #SITC23
Post Carl June, PICI Center Director at Penn Medicine, Recieves 2024 Breakthrough Prize in Life Sciences
Post Developing Next-Gen Scientific Leaders: The Parker Institute for Cancer Immunotherapy Awards up to $2.9 Million to Eight Early Career Investigators
Post Guardant Health and PICI Launch Research Collaboration To Study Connection Between Cancer Biomarkers and Immunotherapy Treatment Response
Post Carl June, PICI Center Director at Penn Medicine, Receives AACR Lifetime Achievement Award in Cancer Research
Post PICI Network Researchers to Present at 2022 Annual Meeting of Society for Immunotherapy of Cancer #SITC22
Post PICI Welcomes Dana-Farber and Gladstone Institutes to its Network of Leading Experts Advancing Cures for Cancer
Post Parker Institute Researchers Highlighted at CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference #CICON22
Post LumaBridge and the Parker Institute for Cancer Immunotherapy Form Strategic Alliance to Speed Access to Clinical Trial Services for Partners
Post Empowering Tomorrow’s Great Minds in Cancer Research: The Parker Institute for Cancer Immunotherapy Awards up to $4.5 Million to Nine Early Career Researchers
Post Resilience, a well-funded manufacturing startup, joins with the Parker Institute to make cancer drugs
Post The Parker Institute for Cancer Immunotherapy and Resilience Announce Strategic Alliance to Develop Next-Generation Cancer Therapies
Post Biomarkers May Predict Better Immunotherapy Treatment Outcomes for Certain Patients with Pancreatic Cancer
Post The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute Announce First Patients Dosed in First-Line Pancreatic Cancer Platform Trial
Post NanoString Technologies, Parker Institute for Cancer Immunotherapy Partner on Cell Therapy Project
Post NanoString and Parker Institute for Cancer Immunotherapy Collaborate to Optimize Cell Therapies to Treat Cancer
Post NanoString and Parker Institute for Cancer Immunotherapy Collaborate to Optimize Cell Therapies to Treat Cancer
Post PICI Makes Progress in Toughest Tumor Types with Pancreatic Cancer Combo, Immune Activity in Cold Tumors
Post Empowering Pancreatic Cancer Patients and Delivering Innovative Immunotherapies: 1440 Foundation
Post Glowing tumor-munching cells, captured on video, show the promise of a new approach to CAR-T cancer therapy
Post Funding the Future of Cancer Research: The Parker Institute for Cancer Immunotherapy Awards Nearly $3 Million to Six Early Career Researchers
Post Improving Conventional Wisdom: From CAR-T Therapy to Diversity in STEM, Avery Posey Has Big Ideas
Post Ute Dugan Joins the Parker Institute for Cancer Immunotherapy as Senior Vice President of Clinical Research
Post Ute Dugan Joins the Parker Institute for Cancer Immunotherapy as Senior Vice President of Clinical Research
Post Gen Next: A new generation of entrepreneurial and innovative donors is stepping forward to carry UCLA Health’s rich tradition of philanthropy into the future
Post A Legacy of Service: How One Woman’s Journey Could Help Bring a New Day for Pancreatic Cancer Patients
Post The international neoantigen initiative Tumour Neoantigen Selection Alliance (TESLA) has identified key parameters for immunotherapy advancement.
Post Parker Institute summoned the neoantigen pioneers to compare their prediction algorithms. And they have some suggestions for the field
Post An Initiative Led by Parker Institute for Cancer Immunotherapy and Cancer Research Institute Discovers Keys That Could Unlock Better Personalized Treatments to Destroy Cancer
Post The Parker Institute for Cancer Immunotherapy Appoints John Connolly, PhD, as Chief Scientific Officer
Post Turning cancer into a curable disease: Immunotherapy expert John Connolly picks up the reins as the new CSO of Sean Parker’s cancer institute
Post The Parker Institute for Cancer Immunotherapy Appoints Immunotherapy Expert John Connolly as Chief Scientific Officer
Post How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease
Post Parker Institute for Cancer Immunotherapy Appoints Frederic Pla, PhD, as Chief Operating Officer
Post CPRIT Awards $19.6 Million to MD Anderson, Sidney Kimmel Establishes Philadelphia T-cell Lymphoma/Leukemia Initiative, and more
Post Frederic Pla enlisted as COO at the Parker Institute; Former Alkermes exec named CMO at Seres Therapeutics
Post The Parker Institute for Cancer Immunotherapy Appoints Seasoned Health Care Leader Frederic Pla as Chief Operating Officer
Post The Parker Institute for Cancer Immunotherapy Awards $2.75 Million to Support Six Early-Career Researchers
Post The Parker Institute for Cancer Immunotherapy Awards $2.75 Million to Support Six Early Career Researchers from Leading Research Institutions
Post The top 10 most popular Endpoints News pieces of 2019 — going viral is a whole new game in biopharma now
Post CRISPR-edited T-cells Safely, Effectively Target Cancer Cells in Myeloma Patients, Early Phase 1 Data Suggests
Post Early Results from First-In-U.S. Trial of CRISPR-Edited Immune Cells for Cancer Patients Suggest Safety of Approach
Post 42nd U.S. President Bill Clinton to Join the TIME 100 Health Summit in New York, NY on October 17
Post Sean Parker helps create a CRISPRed cell therapy 2.0 play — and he’s got a high-profile set of leaders on the team
Post Al Gore on Impeachment, Adam Silver on China and Selma Blair on Her MS Diagnosis: Here Are Biggest Moments From the TIME 100 Health Summit
Post Close to a decade after Eli Lilly killed it, Jeffrey Bluestone’s ‘breakthrough’ drug is back and being steered to the FDA
Post PACT Pharma says it’s perfected the tech to select neoantigens for personalized therapy — now onto the clinic
Post Billionaire Sean Parker is nerding out on cancer research. Science has never seen anyone quite like him
Post Researchers identify three-drug combination that helps curb the growth of deadly type of skin cancer
Post Immunotherapy is fighting cancer but leaving 1% of patients with diabetes – and scientists ‘have no idea why’
Post A lifesaver with a catch: Powerful new cancer drugs can trigger diabetes — and no one is certain why
Post Parker Institute for Cancer Immunotherapy, JDRF and the Helmsley Charitable Trust Form Cancer and Diabetes Research Initiative
Post Inspired by the microbiome, can poop pills and gut bugs help boost cancer immunotherapy’s effects?
Post Researcher comment: The impact of lifestyle factors on the gut microbiome and immunotherapy response
Post Immunotherapy, chemotherapy combination shows promising antitumor activity in metastatic pancreatic cancer
Post The Parker Institute touts early results in pancreatic cancer trial — and a new model to accelerate drug development
Post For Advanced Pancreatic Cancer, Combining Immunotherapies with Chemotherapy Shows Early Promise in Reducing Tumor Size
Post After a 33-year odyssey, Jeffrey Bluestone grabs a ringside seat to watch his drug teplizumab go back into the clinic
Post Parker Institute to Share Pancreatic Cancer Trial Results, Microbiome and Immunotherapy Research, and New CAR-T Approaches at AACR 2019
Post From Bench to Bedside: Dr. Padmanee Sharma Talks Biomarkers, Broken Arms and Being the Nobelle of the Ball
Post PICI President and CEO Jeffrey Bluestone To Be Honored with the AACR-Irving Weinstein Foundation Distinguished Lectureship
Post Billionaire Sean Parker calls China’s gene-edited babies ‘Sputnik 2.0,’ praises FDA, and offers career advice for millennials
Post The Parker Institute for Cancer Immunotherapy Expands its Network to Include More Rising Stars in Cancer Immunotherapy
Post Tech How Sean Parker is working to build ‘a clone army of cancer-killing assassins’ for patients
Post The sandbox: Parker Institute throws its research muscle behind gene therapy tech for destroying cancer cells
Post PsiOxus Therapeutics to Collaborate with the Parker Institute for Cancer Immunotherapy on Virus-Based Gene Therapy to Treat Solid Tumors
Post The Parker Institute for Cancer Immunotherapy Partners with Xyphos Biosciences to Develop Universal Programmable CAR-T Cells for Cancer Treatment
Post James Allison, Parker Institute for Cancer Immunotherapy Director, Wins 2018 Nobel Prize in Medicine or Physiology for Research on Immune Checkpoint Inhibitors
Post Parker Institute Researchers Featured at Fourth International Immunotherapy Conference 2018 in New York #CICON18
Post CAR-T pioneer on riding the NIH roller coaster, speaking up for science, and his funder Sean Parker
Post Parker Institute scientists herald a cell therapy breakthrough in the lab, using next-gen CRISPR tech to engineer T cells
Post PICI Scientist at Dana-Farber Cancer Institute Unravels Structure of Key Cancer Detection Protein in Immune System
Post Neoantigen pioneer Neon Therapeutics casts off in search of $115M IPO to fuel the race to a personalized cancer treatment
Post Parker Institute for Cancer Immunotherapy Scientists Present at ASCO 2018 on Gene Editing in Cell Therapy, Novel Checkpoint Inhibitor Combinations and Other Advances in Immuno-Oncology
Post Parker Institute for Cancer Immunotherapy Scientists to Present Immuno-oncology Research on Personalized Cancer Vaccines, New Checkpoint Inhibitor Combinations, the Microbiome and Cell Therapy at AACR 2018
Post Parker Institute for Cancer Immunotherapy Scientist Kole Roybal of UCSF Wins Inaugural Sartorius & Science Prize for Regenerative Medicine & Cell Therapy
Post “The NIH is in danger of losing its edge in creating biomedical innovations” OpEd published in STAT News
Post CD22 CAR-T Therapy Shows Results in Leukemia, Study Shows, But Could a Dual CAR-T Deliver the One-Two Punch to Avoid Relapse?
Post Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-Oncology
Post Higher Diversity of Gut Microbes, More Faecalibacteria Linked to Better Response to Cancer Immunotherapy, Study Shows
Post Parker Institute for Cancer Immunotherapy Researchers Present Findings on Pancreatic Cancer, Tumor Vaccines and CAR-T at 2017 Society for Immunotherapy of Cancer Annual Meeting
Post The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute Announce First Patients Treated in Pancreatic Cancer Clinical Trial Combining Immunotherapy and Chemotherapy
Post Choosing Therapies à la CAR-T A: Plethora of New Cancer Treatments Is Under Development: There Will Be More Cures, And They Will Be Expensive
Post Unleash The T-Cells: Enrolling The Immune System In The Fight Against Cancer: It Can Have Spectacular Results
Post Using Yourself to Fight Cancer with Jeff Bluestone, President and CEO of the Parker Institute for Cancer Immunotherapy
Post The Parker Institute for Cancer Immunotherapy Trains the Next Generation of Scientific Leaders in Cancer Immunotherapy
Post Billionaire-backed Parker Institute tackles the Holy Grail of cancer R&D — with a virtual unknown
Post Tessa Therapeutics, Parker Institute partner to jointly advance research in cancer immunotherapy
Post Tessa Therapeutics and Parker Institute for Cancer Immunotherapy Enter into Strategic Alliance Agreement
Post The Bio-Tech Bridge – How Tech Philanthropists Are Becoming New Players In The Biotech Ecosystem
Post Parker Institute for Cancer Immunotherapy Scientists to Present Research at ASCO 2017 on IDO Pathway Inhibitors, Novel CAR-Ts and the Microbiome’s Potential in Immunotherapy
Post Parker Institute for Cancer Immunotherapy Bioinformatics Vice President Nikesh Kotecha to speak at Stanford Big Data conference
Post Kronprinsessan delar ut Crafoordpriset i polyartrit (“Crown Princess Awards Crafoord Prize in Polyarthritis”)
Post Sean Parker’s cancer institute may have found a blood test to see if patients will respond to treatment
Post Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and the Cancer Research Institute Announce Collaboration to Accelerate Immuno-Oncology Research
Post Parker Institute for Cancer Immunotherapy Scientists to Present Research on Checkpoint Inhibitors, Adoptive Cell Therapy and Other Advances in Immuno-oncology at AACR 2017
Post Sean and Alexandra Parker, Gwyneth Paltrow to be honored at UCLA Mattel Children’s Hospital event
Post There could be a surprising link between how people respond to a new cancer treatment and their microbiome
Post Parker Institute for Cancer Immunotherapy Named to Top 10 List of Most Innovative Companies in Biotech by Fast Company
Post All Antigens Are Not Created Equal | Unique Tumor Mutations Called Neoantigens Could Hold the Key to Personalized Cancer Therapies
Post A new kind of cancer treatment works remarkably well for some patients but not others — and researchers want to know why
Post The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute announced a collaboration focused on neoantigens
Post Parker Institute for Cancer Immunotherapy and Cancer Research Institute Launch Collaboration on Cancer Neoantigens
Post The Emergence of Philanthropy to Fund High-Risk, High-Reward Cancer Research A Conversation With Jeffrey Bluestone, PhD
Post Parker Institute for Cancer Immunotherapy Featured in “The Cutting Edge of Cancer with Robin Roberts”
Post Parker Institute for Cancer Immunotherapy Aims to Speed Up Cancer Research Trials by Adopting Streamlined Review Process
Post Napster founder to visit Penn for Philly launch of cancer-curing initiative he funded with $250 million
Post Friends and Parker Institute for Cancer Immunotherapy Co-Host Summit: Optimizing the Use of Immunotherapy
Post Jeff Bluestone Honored as a 2016 Thomson Reuters Citation Laureate; Jim Allison of MD Anderson Cancer Center and Craig Thompson of Memorial Sloan Kettering Cancer Center also recognized
Post Culture and commerce collide at the third Vanity Fair New Establishment Summit in San Francisco this October.
Post UCLA study unlocks key mechanisms that determine acquired resistance to immunotherapy in advanced melanoma
Post A Sean Parker-backed cancer trial that would use CRISPR in humans for the first time just got a critical approval
Post Vice President Biden provides extensive comments about the collaborative model set up by the Parker Institute